2型糖尿病患者使用SGLT2抑制剂与DPP-4抑制剂的痴呆风险:系统性审查和元分析.
Kiran Kumari1, Anusha Bai2, Fnu Geeta2
1Ziauddin Medical University, Karachi, Pakistan.
Endocrinology, diabetes & metabolism
|March 4, 2026
概括
与二二酶-4 (DPP-4) 抑制剂相比,-葡萄糖共运输体-2 (SGLT2) 抑制剂在2型糖尿病患者中显著降低痴呆症风险. 这一发现表明SGLT2抑制剂的潜在神经保护益处.
科学领域:
- 内分泌学 在内分泌学.
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
背景情况:
- 2型糖尿病 (T2DM) 是一种已知的痴呆症风险因素.
- 降血糖疗法的认知影响尚未完全理解.
- -葡萄糖共运输体-2 (SGLT2) 抑制剂可能会提供神经保护,而不是二二基化酶-4 (DPP-4) 抑制剂.
研究的目的:
- 为了比较T2DM患者发病痴呆的风险,开始使用SGLT2抑制剂与DPP-4抑制剂.
- 研究SGLT2抑制剂与痴呆风险之间的关联.
- 评估降血糖疗法对认知衰退的影响.
主要方法:
- 通过PubMed,Scopus和Cochrane中央注册的系统文献搜索,直到2025年6月1日.
- 主要结局:全因性痴呆;次要结局:阿尔茨海默病,血管性痴呆.
- 随机效应模型用于组合调整后的危险比率 (HRs);进行了子组分析.
主要成果:
- 九个回顾性队列研究包括2,433,086个人.
- 与DPP-4抑制剂相比,SGLT2抑制剂与所有原因痴呆 (HR=0.74),阿尔茨海默氏症 (HR=0.62) 和血管痴呆 (HR=0.54) 的风险显著降低.
- 达帕格利弗洛辛和恩帕格利弗洛辛显示有益处;卡纳格利弗洛辛没有. 调查结果在各个年龄和性别小组中一致.
结论:
- 与DPP-4抑制剂相比,SGLT2抑制剂与T2DM患者的痴呆风险降低有关.
- SGLT2 抑制剂的潜在神经保护作用需要进一步研究.
- 需要进行前性试验来确认发现并阐明机制.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Diabetes: Symptoms, Diagnosis, and Complications
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is based on...
Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

